New  	New  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
anticoagulants  	anticoagulants  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
thromboembolism  	thromboembolism  	 NN	B-NP
in  	in  	 IN	O
atrial  	atrial  	 JJ	B-NP
fibrillation 	fibrillation 	 NN	I-NP
:  	:  	 :	O
from  	from  	 IN	O
clinical  	clinical  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
to  	to  	 TO	O
appropriate  	appropriate  	 JJ	O
use  	use  	 NN	O
The  	The  	 DT	O
large  	large  	 JJ	O
amount  	amount  	 NN	O
of  	of  	 IN	O
data  	data  	 NNS	O
on  	on  	 IN	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants  	anticoagulants  	 JJ	I-NP
deriving  	deriving  	 NN	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
RE-LY 	RE-LY 	 JJ	B-NP
,  	,  	 ,	O
ROCKET  	ROCKET  	 NNP	B-NP
AF  	AF  	 NNP	I-NP
and  	and  	 CC	O
ARISTOTLE  	ARISTOTLE  	 NNP	B-NP
studies 	studies 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
patient  	patient  	 JJ	O
subgroups  	subgroups  	 NNS	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
latest  	latest  	 JJS	O
guidelines  	guidelines  	 NNS	O
on  	on  	 IN	O
atrial  	atrial  	 JJ	B-NP
fibrillation  	fibrillation  	 NNS	I-NP
( 	( 	 -LRB-	O
AF 	AF 	 NNP	B-NP
)  	)  	 -RRB-	O
issued  	issued  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
major  	major  	 JJ	O
international  	international  	 JJ	O
cardiology  	cardiology  	 JJ	B-NP
societies  	societies  	 NNS	I-NP
created  	created  	 VBD	O
the  	the  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
this  	this  	 DT	O
special  	special  	 JJ	O
issue 	issue 	 NN	O
.  	.  	 .	O
Regulatory  	Regulatory  	 JJ	B-NP
approval  	approval  	 NN	I-NP
and  	and  	 CC	O
reimbursement  	reimbursement  	 NN	B-NP
within  	within  	 IN	O
the  	the  	 DT	O
National  	National  	 NNP	B-NP
Healthcare  	Healthcare  	 NNP	I-NP
System  	System  	 NNP	I-NP
of  	of  	 IN	O
these  	these  	 DT	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants  	anticoagulants  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
AF  	AF  	 NNP	B-NP
at  	at  	 IN	O
risk  	risk  	 NN	O
of  	of  	 IN	O
stroke  	stroke  	 NNS	O
are  	are  	 VBP	O
expected  	expected  	 VBN	O
to  	to  	 TO	O
progressively  	progressively  	 RB	O
modify  	modify  	 VB	O
anticoagulant  	anticoagulant  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	O
most  	most  	 JJS	O
patients  	patients  	 NNS	O
on  	on  	 IN	O
warfarin  	warfarin  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
evolution  	evolution  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
approach  	approach  	 NN	I-NP
to  	to  	 TO	O
AF  	AF  	 NNP	B-NP
is  	is  	 VBZ	O
primarily  	primarily  	 RB	O
driven  	driven  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
improved  	improved  	 JJ	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
novel  	novel  	 NN	O
agents  	agents  	 NNS	O
that  	that  	 IN	O
results  	results  	 NNS	O
in  	in  	 IN	O
reduced  	reduced  	 JJ	O
thromboembolic  	thromboembolic  	 NN	B-NP
and  	and  	 CC	O
bleeding  	bleeding  	 VBG	B-NP
risk 	risk 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
their  	their  	 PRP$	O
ease  	ease  	 NN	O
of  	of  	 IN	O
administration  	administration  	 NN	B-NP
and  	and  	 CC	O
freedom  	freedom  	 NN	O
from  	from  	 IN	O
laboratory  	laboratory  	 NN	O
monitoring 	monitoring 	 NN	O
.  	.  	 .	O
When  	When  	 WRB	O
anticoagulation  	anticoagulation  	 NN	B-NP
is  	is  	 VBZ	O
indicated 	indicated 	 VBN	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
currently  	currently  	 RB	O
suggested  	suggested  	 VBN	O
to  	to  	 TO	O
replace  	replace  	 VB	O
dose-adjusted  	dose-adjusted  	 JJ	O
warfarin  	warfarin  	 NN	B-NP
with  	with  	 IN	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants 	anticoagulants 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
no  	no  	 DT	O
data  	data  	 NNS	O
from  	from  	 IN	O
comparative  	comparative  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
among  	among  	 IN	O
new  	new  	 JJ	O
anticoagulants  	anticoagulants  	 NNS	B-NP
are  	are  	 VBP	O
available 	available 	 JJ	O
,  	,  	 ,	O
the  	the  	 DT	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
will  	will  	 MD	O
help  	help  	 VB	O
clinicians  	clinicians  	 VBN	O
to  	to  	 TO	O
tailor  	tailor  	 VB	O
therapy  	therapy  	 NN	O
to  	to  	 TO	O
individual  	individual  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
by  	by  	 IN	O
choosing  	choosing  	 VBG	O
the  	the  	 DT	O
most  	most  	 RBS	O
effective  	effective  	 JJ	O
drug  	drug  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
appropriate  	appropriate  	 JJ	O
dosage 	dosage 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
review  	review  	 NN	O
describes  	describes  	 VBZ	O
different  	different  	 JJ	O
algorithms  	algorithms  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
new  	new  	 JJ	O
oral  	oral  	 JJ	B-NP
anticoagulants  	anticoagulants  	 NN	I-NP
in  	in  	 IN	O
everyday  	everyday  	 JJ	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
,  	,  	 ,	O
also  	also  	 RB	O
in  	in  	 IN	O
AF  	AF  	 NNP	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
concomitant  	concomitant  	 JJ	O
renal  	renal  	 JJ	B-NP
dysfunction 	dysfunction 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
special  	special  	 JJ	O
focus  	focus  	 NN	O
on  	on  	 IN	O
drug  	drug  	 NN	B-NP
interactions  	interactions  	 NNS	I-NP
and  	and  	 CC	O
bleeding  	bleeding  	 VBG	B-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
